« Neurotech in Japan and Emerging Schizophrenia Treatments |
| Apple - Beyond Ipod to Open Source NeuroLens »
October 7, 2005
How We Are Going to Die
This past Sunday, David Brooks in the New York Times explains how we are going to die:
"Twenty percent of us, according to a Rand Corporation study, are going to get cancer or another rapidly debilitating condition and we'll be dead within a year of getting the disease. Another 20 percent of us are going to suffer from some cardiac or respiratory failure. We'll suffer years of worsening symptoms, a few
life-threatening episodes, and then eventually die.
But 40 percent of us will suffer from some form of dementia (most frequently Alzheimer's disease or a disabling stroke). Our gradual, unrelenting path toward death will take 8 or 10 or even 20 years, during which we will cease to become the person we were. We will linger on, in some new state, depending on the care of others.
As the population ages, more people will live in this final category. Between now and 2050, the percentage of the population above age 85 is expected to quadruple, and the number of people with Alzheimer's
disease is expected to quadruple, too."
Bottom line: Neurological diseases and psychiatric illnesses represent the greatest threat to our lifestyles and economy. Beyond the untold human suffering, the economic burden of brain-related illness is already greater than $1 Trllion. What will it be in 2050?
+ TrackBacks (0) | Category: Mental Health Issues
POST A COMMENT
Thanks for signing in,
Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)
- RELATED ENTRIES
- Neurotech 2010: Translational Researchers Highlight Innovation
- The Neuro Revolution in China Progressing
- Speakers for Neurotech 2010 - Boston, May 19-20
- Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
- McGovern Institue for Brain Research at MIT Goes Web 2.0
- The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
- Neuropharma FDA Approvals Down in 2009
- Tel Aviv Neurotech Cluster Thrives